Stroke risk in multiple sclerosis: a critical appraisal of the literature

References

• Sacco RL, Benjamin EJ, Broderick JP, et al. American Heart Association Prevention Conference. IV. Prevention and rehabilitation of stroke. Risk factors. Stroke. 1997;28(7):1507–1517.
   PubMed Web of Science ®Google Scholar
• Boehme AK, Esenwa C, Elkind MSV. Stroke risk factors, genetics, and prevention. Circ Res. 2017;120(3):472–495.
   PubMed Web of Science ®Google Scholar
• Wafa HA, Wolfe CDA, Emmett E, et al. Burden of stroke in Europe: thirty-year projections of incidence, prevalence, deaths, and disability-adjusted life years. Stroke. 2020;51(8):2418–2427.
   PubMed Web of Science ®Google Scholar
• Appelros P, Stegmayr B, Terént A. Sex differences in stroke epidemiology: a systematic review. Stroke. 2009;40(4):1082–1090.
   PubMed Web of Science ®Google Scholar
• Marrugat J, Arboix A, García-Eroles L, et al. [The estimated incidence and case fatality rate of ischemic and hemorrhagic cerebrovascular disease in 2002 in Catalonia]. Rev Esp Cardiol. 2007;60(6):573–580.
   PubMed Web of Science ®Google Scholar
• Parikh Neal S, Merkler Alexander E, Iadecola C. Inflammation, autoimmunity, infection, and stroke: epidemiology and lessons from therapeutic intervention, autoimmunity, infection, and stroke. Stroke. 2020;51(3):711–718.
   PubMed Web of Science ®Google Scholar
• Putnam T. Lesions of encephalomyelitis and multiple sclerosis: venous thrombosis as the primary alteration. JAMA. 1937;108(18):1477–1480.
   Google Scholar
• Koudriavtseva T. Thrombotic processes in multiple sclerosis as manifestation of innate immune activation. Front Neurol. 2014;5:119–119.
   PubMed Web of Science ®Google Scholar
• Sternberg Z. Genetic, epigenetic, and environmental factors influencing neurovisceral integration of cardiovascular modulation: Focus on multiple sclerosis. Neuromolecular Med. 2016;18(1):16–36.
   PubMed Web of Science ®Google Scholar
• van Noort JM, Baker D, Amor S. Mechanisms in the development of multiple sclerosis lesions: reconciling autoimmune and neurodegenerative factors. CNS Neurol Disord Drug Targets. 2012;11(5):556–569.
   PubMed Web of Science ®Google Scholar
• Christiansen CF. Risk of vascular disease in patients with multiple sclerosis: a review. Neurol Res. 2012;34(8):746–753.
   PubMed Web of Science ®Google Scholar
• Petersen MA, Ryu JK, Akassoglou K. Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics. Nat Rev Neurosci. 2018;19(5):283–301.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang F, Huang D, et al. Contribution of gray and white matter abnormalities to cognitive impairment in multiple sclerosis. IJMS. 2016;18(1):46.
   Google Scholar
• Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol. 2009;65(3):239–248.
   PubMed Web of Science ®Google Scholar
• Okuda DT, Mowry EM, Beheshtian A, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology. 2009;72(9):800–805.
   PubMed Web of Science ®Google Scholar
• Jadidi E, Mohammadi M, Moradi T. High risk of cardiovascular diseases after diagnosis of multiple sclerosis. Mult Scler. 2013;19(10):1336–1340.
   PubMed Web of Science ®Google Scholar
• Christiansen CF, Christensen S, Farkas DK, et al. Risk of arterial cardiovascular diseases in patients with multiple sclerosis: a population-based cohort study. Neuroepidemiology. 2010;35(4):267–274.
   PubMed Web of Science ®Google Scholar
• Zöller B, Li X, Sundquist J, et al. Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. BMC Neurol. 2012;12:41–41.
   PubMed Web of Science ®Google Scholar
• Lavela SL, Prohaska TR, Furner S, et al. Chronic diseases in male veterans with multiple sclerosis. Prev Chronic Dis. 2012;9:E55–E55.
   PubMed Web of Science ®Google Scholar
• Allen NB, Lichtman JH, Cohen HW, et al. Vascular disease among hospitalized multiple sclerosis patients. Neuroepidemiology. 2008;30(4):234–238.
   PubMed Web of Science ®Google Scholar
• Thormann A, Magyari M, Koch-Henriksen N, et al. Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark. J Neurol. 2016;263(12):2484–2493.
   PubMed Web of Science ®Google Scholar
• Kang JH, Chen YH, Lin HC. Comorbidities amongst patients with multiple sclerosis: a population-based controlled study. Eur J Neurol. 2010;17(9):1215–1219.
   PubMed Web of Science ®Google Scholar
• Tseng CH, Huang WS, Lin CL, et al. Increased risk of ischaemic stroke among patients with multiple sclerosis. Eur J Neurol. 2015;22(3):500–506.
   PubMed Web of Science ®Google Scholar
• Capkun G, Dahlke F, Lahoz R, et al. Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: an observational study using the US department of defense administrative claims database. Mult Scler Relat Disord. 2015;4(6):546–554.
   PubMed Web of Science ®Google Scholar
• Hong Y, Tang HR, Ma M, et al. Multiple sclerosis and stroke: a systematic review and meta-analysis. BMC Neurol. 2019;19(1):139.
   PubMed Web of Science ®Google Scholar
• Edwards NC, Munsell M, Menzin J, et al. Comorbidity in US patients with multiple sclerosis. PROM. 2018;ume 9:97–102.
   Google Scholar
• Speciale L, Sarasella M, Ruzzante S, et al. Endothelin and nitric oxide levels in cerebrospinal fluid of patients with multiple sclerosis. J Neurovirol. 2000;6(Suppl 2):S62–S6.
   PubMedGoogle Scholar
• Marrie RA, Reider N, Cohen J, et al. A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. Mult Scler. 2015;21(3):318–331.
   PubMed Web of Science ®Google Scholar
• Magyari M, Sorensen PS. Comorbidity in multiple sclerosis. Front Neurol. 2020;11:851–851.
   PubMed Web of Science ®Google Scholar
• Ikram A, Farooqui M, Qeadan F, et al. Abstract WMP55: Increased risk of acute ischemic stroke in multiple sclerosis: Analysis of a large national cohort. Stroke. 2019;50(Suppl_1):AWMP55–AWMP55.
   Google Scholar
• Belliston S, Dubinsky RM, Lynch S. Cerebrovascular comorbidities in multiple sclerosis. Analysis of the nationwide inpatient sample. Neurol Disord Stroke Int. 2018;1(2):1012.
   Google Scholar
• Zulfiqar M, Qeadan F, Ikram A, et al. Intracerebral hemorrhage in multiple sclerosis: a retrospective cohort study. J Stroke Cerebrovasc Dis. 2019;28(2):267–275.
   PubMed Web of Science ®Google Scholar
• Krökki O, Bloigu R, Ansakorpi H, et al. Neurological comorbidity and survival in multiple sclerosis. Mult Scler Relat Disord. 2014;3(1):72–77.
   PubMed Web of Science ®Google Scholar
• Marrie RA, Elliott L, Marriott J, et al. Effect of comorbidity on mortality in multiple sclerosis. Neurology. 2015;85(3):240–247.
   PubMed Web of Science ®Google Scholar
• Roshanisefat H, Bahmanyar S, Hillert J, et al. Multiple sclerosis clinical course and cardiovascular disease risk - Swedish cohort study. Eur J Neurol. 2014;21(11):1353–1e88.
   PubMed Web of Science ®Google Scholar
• Jakimovski D, Topolski M, Genovese AV, et al. Vascular aspects of multiple sclerosis: emphasis on perfusion and cardiovascular comorbidities. Expert Rev Neurother. 2019;19(5):445–458.
   PubMed Web of Science ®Google Scholar
• Marrie RA, Yu BN, Leung S, et al. Prevalence and incidence of ischemic heart disease in multiple sclerosis: a population-based validation study. Mult Scler Relat Disord. 2013;2(4):355–361.
   PubMed Web of Science ®Google Scholar
• Marrie RA, Fisk J, Tremlett H, et al. Differing trends in the incidence of vascular comorbidity in MS and the general population. Neurol Clin Pract. 2016;6(2):120–128.
   PubMedGoogle Scholar
• Ramagopalan SV, Wotton CJ, Handel AE, et al. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med. 2011;9:1.
   PubMed Web of Science ®Google Scholar
• Peeters PJHL, Bazelier MT, Uitdehaag BMJ, et al. The risk of venous thromboembolism in patients with multiple sclerosis: the clinical practice research datalink. J Thromb Haemost. 2014;12(4):444–451.
   PubMed Web of Science ®Google Scholar
• Arpaia G, Bavera PM, Caputo D, et al. Risk of deep venous thrombosis (DVT) in bedridden or wheelchair-bound multiple sclerosis patients: a prospective study. Thromb Res. 2010;125(4):315–317.
   PubMed Web of Science ®Google Scholar
• Kaufman J, Khatri BO, Riendl P. Are patients with multiple sclerosis protected from thrombophlebitis and pulmonary embolism? Chest. 1988;94(5):998–1001.
   PubMed Web of Science ®Google Scholar
• Persson R, Lee S, Yood MU, et al. Incident cardiovascular disease in patients diagnosed with multiple sclerosis: a multi-database study. Mult Scler Relat Disord. 2020;37:101423.
   PubMed Web of Science ®Google Scholar
• Khedr AA, Canaple S, Monet P, et al. MRI and magnetic resonance angiography findings in patients with multiple sclerosis mimicked by stroke. J Clin Neurosci. 2013;20(8):1163–1164.
   PubMed Web of Science ®Google Scholar
• Ifergan H, Amelot A, Ismail M, et al. Stroke-mimics in stroke-units. Evaluation after changes imposed by randomized trials. Arq Neuropsiquiatr. 2020;78(2):88–95.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Fan S, Han F, et al. Paroxysmal symptoms as the first manifestation of multiple sclerosis mimicking a transient ischemic attack: a report of two cases. Front Neurol. 2017;8:585–585.
   PubMed Web of Science ®Google Scholar
• Tettey P, Simpson S, Jr., Taylor BV, et al. Vascular comorbidities in the onset and progression of multiple sclerosis. J Neurol Sci. 2014;347(1-2):23–33.
   PubMed Web of Science ®Google Scholar
• Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology. 2010;74(13):1041–1047.
   PubMed Web of Science ®Google Scholar
• Park K, Bavry AA. Risk of stroke associated with nonsteroidal anti-inflammatory drugs. Vasc Health Risk Manag. 2014;10:25–32.
   PubMedGoogle Scholar
• Christensen S, Farkas DK, Pedersen L, et al. Multiple sclerosis and risk of venous thromboembolism: a population-based cohort study. Neuroepidemiology. 2012;38(2):76–83.
   PubMed Web of Science ®Google Scholar
• Mincu RI, Magda LS, Florescu M, et al. Cardiovascular dysfunction in multiple sclerosis. Maedica (Bucur). 2015;10(4):364–370.
   PubMedGoogle Scholar
• Caprio MG, Russo C, Giugliano A, et al. Vascular disease in patients with multiple sclerosis: a review. Vasc Med Surg. 2016;4(2):1000259.
   Google Scholar
• Ahmed O, Geraldes R, DeLuca GC, et al. Multiple sclerosis and the risk of systemic venous thrombosis: a systematic review. Mult Scler Relat Disord. 2019;27:424–430.
   PubMedGoogle Scholar
• Lalmohamed A, Bazelier MT, Van Staa TP, et al. Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based cohort study. Eur J Neurol. 2012;19(7):1007–1014.
   PubMed Web of Science ®Google Scholar
• Murtonen A, Kurki S, Hänninen K, et al. Common comorbidities and survival in MS: Risk for stroke, type 1 diabetes and infections. Mult Scler Relat Disord. 2018;19:109–114.
   PubMed Web of Science ®Google Scholar
• Kingwell E, Zhu F, Evans C, et al. Causes that contribute to the excess mortality risk in multiple sclerosis: a population-based study. Neuroepidemiology. 2020;54(2):131–139.
   PubMed Web of Science ®Google Scholar
• Lassmann H. Hypoxia-like tissue injury as a component of multiple sclerosis lesions. J Neurol Sci. 2003;206(2):187–191.
   PubMed Web of Science ®Google Scholar
• Celarain N, Tomas-Roig J. Aberrant DNA methylation profile exacerbates inflammation and neurodegeneration in multiple sclerosis patients. J Neuroinflammation. 2020;17(1):21.
   PubMed Web of Science ®Google Scholar
• Handel AE, Handunnetthi L, Giovannoni G, et al. Genetic and environmental factors and the distribution of multiple sclerosis in Europe. Eur J Neurol. 2010;17(9):1210–1214.
   PubMed Web of Science ®Google Scholar
• Alexander JS, Zivadinov R, Maghzi AH, et al. Multiple sclerosis and cerebral endothelial dysfunction: mechanisms. Pathophysiology. 2011;18(1):3–12.
   PubMedGoogle Scholar
• Zhao Z, Nelson AR, Betsholtz C, et al. Establishment and dysfunction of the blood-brain barrier. Cell. 2015;163(5):1064–1078.
   PubMed Web of Science ®Google Scholar
• Sheikh MH, Henson SM, Loiola RA, et al. Immuno-metabolic impact of the multiple sclerosis patients’ sera on endothelial cells of the blood-brain barrier. J Neuroinflammation. 2020;17(1):153.
   PubMed Web of Science ®Google Scholar
• Lopes Pinheiro MA, Kooij G, Mizee MR, et al. Immune cell trafficking across the barriers of the central nervous system in multiple sclerosis and stroke. Biochim Biophys Acta. 2016;1862(3):461–471.
   PubMed Web of Science ®Google Scholar
• Levard D, Buendia I, Lanquetin A, et al. Filling the gaps on stroke research: Focus on inflammation and immunity. Brain Behav Immun. 2021;91:649–667.
   PubMed Web of Science ®Google Scholar
• Plantone D, Inglese M, Salvetti M, et al. A perspective of coagulation dysfunction in multiple sclerosis and in experimental allergic encephalomyelitis. Front Neurol. 2019;9(1175):1175.
   PubMedGoogle Scholar
• Ziliotto N, Bernardi F, Jakimovski D, et al. Coagulation pathways in neurological diseases: multiple sclerosis. Front Neurol. 2019;10:409–409.
   PubMed Web of Science ®Google Scholar
• Koike H, Katsuno M. Macrophages and autoantibodies in demyelinating diseases. Cells. 2021;10(4):844.
   PubMed Web of Science ®Google Scholar
• Zhao J, Roberts A, Wang Z, et al. Emerging role of PD-1 in the central nervous system and brain diseases. Neurosci Bull. 2021;37(8):1188–1202.
   Google Scholar
• Arsovska A, Arsovski Z, Popovski A. 345 autoimmune diseases and risk of stroke. World Allerg Organ J. 2012;5(Suppl 2):S128–S128.
   Google Scholar
• Baena-Díez JM, Garcia-Gil M, Comas-Cufí M, et al. Association between chronic immune-mediated inflammatory diseases and cardiovascular risk. Heart. 2018;104(2):119–126.
   PubMed Web of Science ®Google Scholar
• Khosravaniardakani S, Handjani F, Alimohammadi R, et al. Frequency of neurological disorders in bullous pemphigoid patients: a cross-sectional study. Int Scholar Res Notice. 2017;2017:6053267.
   Google Scholar
• Packer M. Potential role of atrial myopathy in the pathogenesis of stroke in rheumatoid arthritis and psoriasis: a conceptual framework and implications for prophylaxis. J Am Heart Assoc. 2020;9(3):e014764.
   PubMed Web of Science ®Google Scholar
• Sitaru C. Bullous pemphigoid: a prototypical antibody-mediated organ-specific autoimmune disease. J Invest Dermatol. 2009;129(4):822–824.
   PubMed Web of Science ®Google Scholar
• Tarazona M, Mota A, Gripp A, et al. Bullous pemphigoid and neurological disease: statistics from a dermatology service. An Bras Dermatol. 2015;90(2):280–282.
   PubMed Web of Science ®Google Scholar
• Yang Y-W, Chen Y-H, Xirasagar S, et al. Increased risk of stroke in patients with bullous pemphigoid. Stroke. 2011;42(2):319–323.
   PubMed Web of Science ®Google Scholar
• Zha AM, Di Napoli M, Behrouz R. Prevention of stroke in rheumatoid arthritis. Curr Neurol Neurosci Rep. 2015;15(12):77.
   PubMed Web of Science ®Google Scholar
• Hsu PS, Lin HH, Li CR, et al. Increased risk of stroke in patients with osteoarthritis: a population-based cohort study. Osteoarthr Cartil. 2017;25(7):1026–1031.
   PubMed Web of Science ®Google Scholar
• Boehncke W-H. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: Causes and consequences. Front Immunol. 2018;9:579.
   PubMed Web of Science ®Google Scholar
• Wiseman SJ, Ralston SH, Wardlaw JM. Cerebrovascular disease in rheumatic diseases. Stroke. 2016;47(4):943–950.
   PubMed Web of Science ®Google Scholar
• Maher P, Currais A, Schubert D. Using the oxytosis/ferroptosis pathway to understand and treat age-associated neurodegenerative diseases. Cell Chem Biol. 2020;27(12):1456–1471.
   PubMed Web of Science ®Google Scholar
• Ren JX, Li C, Yan XL, et al. Crosstalk between oxidative stress and ferroptosis/oxytosis in ischemic stroke: possible targets and molecular mechanisms. Oxid Med Cell Longev. 2021;2021:6643382.
   PubMed Web of Science ®Google Scholar
• Alfieri DF, Lehmann MF, Flauzino T, et al. Immune-Inflammatory, metabolic, oxidative, and nitrosative stress biomarkers predict acute ischemic stroke and short-term outcome. Neurotox Res. 2020;38(2):330–343.
   PubMed Web of Science ®Google Scholar
• Flauzino T, Simão ANC, de Carvalho Jennings Pereira WL, et al. Disability in multiple sclerosis is associated with age and inflammatory, metabolic and oxidative/nitrosative stress biomarkers: results of multivariate and machine learning procedures. Metab Brain Dis. 2019;34(5):1401–1413.
   PubMed Web of Science ®Google Scholar
• Reiche EMV, Gelinksi JR, Alfieri DF, et al. Immune-inflammatory, oxidative stress and biochemical biomarkers predict short-term acute ischemic stroke death. Metab Brain Dis. 2019;34(3):789–804.
   PubMed Web of Science ®Google Scholar
• Carbonell T, Rama R. Iron, oxidative stress and early neurological deterioration in ischemic stroke. Curr Med Chem. 2007;14(8):857–874.
   PubMed Web of Science ®Google Scholar
• Tan Q, Fang Y, Gu Q. Mechanisms of modulation of ferroptosis and its role in central nervous system diseases. Front Pharmacol. 2021;12:657033.
   PubMed Web of Science ®Google Scholar
• Sen MK, Almuslehi MSM, Shortland PJ, et al. Revisiting the pathoetiology of multiple sclerosis: Has the tail been wagging the mouse? Front Immunol. 2020;11(2374):572186.
   PubMedGoogle Scholar
• Balasa R, Barcutean L, Balasa A, et al. The action of TH17 cells on blood brain barrier in multiple sclerosis and experimental autoimmune encephalomyelitis. Hum Immunol. 2020;81(5):237–243.
   PubMed Web of Science ®Google Scholar
• Jadidi-Niaragh F, Mirshafiey A. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand J Immunol. 2011;74(1):1–13.
   PubMed Web of Science ®Google Scholar
• Xu S, Cao X. Interleukin-17 and its expanding biological functions. Cell Mol Immunol. 2010;7(3):164–174.
   PubMed Web of Science ®Google Scholar
• Pawluk H, Woźniak A, Grześk G, et al. The role of selected pro-inflammatory cytokines in pathogenesis of ischemic stroke. Clin Interv Aging. 2020;15:469–484.
   PubMed Web of Science ®Google Scholar
• Lambertsen KL, Biber K, Finsen B. Inflammatory cytokines in experimental and human stroke. J Cereb Blood Flow Metab. 2012;32(9):1677–1698.
   PubMed Web of Science ®Google Scholar
• Ramiro L, Abraira L, Quintana M, et al. Blood biomarkers to predict long-term mortality after ischemic stroke. Life (Basel. 2021;11(2):135. ).
   PubMed Web of Science ®Google Scholar
• Horstman LL, Jy W, Ahn YS, et al. Role of platelets in neuroinflammation: a wide-angle perspective. J Neuroinflammation. 2010;7(1):10.
   PubMedGoogle Scholar
• Saluk-Bijak J, Dziedzic A, Bijak M. Pro-thrombotic activity of blood platelets in multiple sclerosis. Cells. 2019;8(2):110.
   PubMed Web of Science ®Google Scholar
• Sheremata WA, Jy W, Horstman LL, et al. Evidence of platelet activation in multiple sclerosis. J Neuroinflammation. 2008;5(1):27.
   PubMedGoogle Scholar
• Vries H, Schwaninger M. Neuroinflammation: a common denominator for stroke, multiple sclerosis and alzheimer’s disease. Biochimica Biophysica Acta (BBA) Mol Basis Dis. 2016;1862(3):297–298.
   PubMed Web of Science ®Google Scholar
• Rawish E, Nording H, Münte T, et al. Platelets as mediators of neuroinflammation and thrombosis. Front Immunol. 2020;11:548631.
   PubMed Web of Science ®Google Scholar
• Kocovski P, Jiang X, D’Souza C, et al. Platelet depletion is effective in ameliorating anxiety-like behavior and reducing the Pro-Inflammatory environment in the hippocampus in murine experimental autoimmune encephalomyelitis. JCM. 2019;8(2):162.
   Google Scholar
• Dziedzic A, Miller E, Bijak M, et al. Increased Pro-Thrombotic platelet activity associated with thrombin/PAR1-dependent pathway disorder in patients with secondary progressive multiple sclerosis. Int J Mol Sci. 2020;21(20):7722.
   Web of Science ®Google Scholar
• Han MH, Hwang SI, Roy DB, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature. 2008;451(7182):1076–1081.
   PubMed Web of Science ®Google Scholar
• Frischer JM, Weigand SD, Guo Y, et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. 2015;78(5):710–721.
   PubMed Web of Science ®Google Scholar
• Lassmann H, van Horssen J. Oxidative stress and its impact on neurons and glia in multiple sclerosis lesions. Biochim Biophys Acta. 2016;1862(3):506–510.
   PubMed Web of Science ®Google Scholar
• Choi IY, Lee P, Adany P, et al. In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis. Mult Scler. 2018;24(8):1029–1038.
   PubMed Web of Science ®Google Scholar
• Dziedzic A, Morel A, Miller E, et al. Oxidative damage of blood platelets correlates with the degree of ­psychophysical disability in secondary progressive multiple sclerosis. Oxid Med Cell Longev. 2020;2020:1–12.
   Web of Science ®Google Scholar
• Mezzaroba L, Simão ANC, Oliveira SR, et al. Antioxidant and anti-inflammatory diagnostic biomarkers in multiple sclerosis: a machine learning study. Mol Neurobiol. 2020;57(5):2167–2178.
   PubMed Web of Science ®Google Scholar
• de Carvalho Jennings Pereira WL, Flauzino T, Alfieri DF, et al. Immune-inflammatory, metabolic and hormonal biomarkers are associated with the clinical forms and disability progression in patients with multiple sclerosis: a follow-up study. J Neurol Sci. 2020;410:116630.
   PubMed Web of Science ®Google Scholar
• Stoessel D, Stellmann JP, Willing A, et al. Metabolomic profiles for primary progressive multiple sclerosis stratification and disease course monitoring. Front Hum Neurosci. 2018;12:226.
   PubMed Web of Science ®Google Scholar
• Del Boccio P, Pieragostino D, Di Ioia M, et al. Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis. J Proteomics. 2011;74(12):2826–2836.
   PubMed Web of Science ®Google Scholar
• Andreoli VM, Maffei F, Tonon GC, et al. Significance of plasma lysolecithin in patients with multiple sclerosis: a longitudinal study. J Neurol Neurosurg Psychiatry. 1973;36(4):661–667.
   PubMed Web of Science ®Google Scholar
• Farooqui AA, Horrocks LA. Phospholipase A2-generated lipid mediators in the brain: the good, the bad, and the ugly. Neuroscientist. 2006;12(3):245–260.
   PubMed Web of Science ®Google Scholar
• Sternberg Z, Drake A, Sternberg DS, et al. Lp-PLA2: inflammatory biomarker of vascular risk in multiple sclerosis. J Clin Immunol. 2012;32(3):497–504.
   PubMed Web of Science ®Google Scholar
• Li H, Chen L, Ma X, et al. Shared gene expression between multiple sclerosis and ischemic stroke. Front Genet. 2019;9:598–598.
   PubMed Web of Science ®Google Scholar
• Tian Z, Song Y, Yao Y, et al. Genetic etiology shared by multiple sclerosis and ischemic stroke. Front Genet. 2020;11:646.
   PubMed Web of Science ®Google Scholar
• Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476(7359):214–219.
   PubMed Web of Science ®Google Scholar
• Albrekkan FM, Bachir S, Jumaa MA, et al. Is there a genetic correlation between multiple sclerosis and cerebral aneurysms? World Neurosurg. 2016;95:624.e1–e4.
   PubMed Web of Science ®Google Scholar
• Tseveleki V, Rubio R, Vamvakas S-S, et al. Comparative gene expression analysis in mouse models for multiple sclerosis, alzheimer’s disease and stroke for identifying commonly regulated and disease-specific gene changes. Genomics. 2010;96(2):82–91.
   PubMed Web of Science ®Google Scholar
• Reeves MJ, Bushnell CD, Howard G, et al. Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol. 2008;7(10):915–926.
   PubMed Web of Science ®Google Scholar
• Arboix A, Cartanyà A, Lowak M, et al. Gender differences and woman-specific trends in acute stroke: results from a hospital-based registry (1986-2009. Clin Neurol Neurosurg. 2014;127:19–24. )
   PubMed Web of Science ®Google Scholar
• Harbo HF, Gold R, Tintoré M. Sex and gender issues in multiple sclerosis. Ther Adv Neurol Disord. 2013;6(4):237–248.
   PubMed Web of Science ®Google Scholar
• Liu S, Chan W-S, Ray JG, et al. Stroke and cerebrovascular disease in pregnancy. Stroke. 2019;50(1):13–20.
   Web of Science ®Google Scholar
• Nguyen AL, Vodehnalova K, Kalincik T, et al. Association of pregnancy with the onset of clinically isolated syndrome. JAMA Neurol. 2020;77(12):1496–1503.
   PubMed Web of Science ®Google Scholar
• Lebrun C, Le Page E, Kantarci O, et al. Impact of pregnancy on conversion to clinically isolated syndrome in a radiologically isolated syndrome cohort. Mult Scler. 2012;18(9):1297–1302.
   PubMed Web of Science ®Google Scholar
• Pinhas-Hamiel O, Livne M, Harari G, et al. Prevalence of overweight, obesity and metabolic syndrome components in multiple sclerosis patients with significant disability. Eur J Neurol. 2015;22(9):1275–1279.
   PubMed Web of Science ®Google Scholar
• Amato MP, Derfuss T, Hemmer B, et al. Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. Mult Scler. 2018;24(5):590–603.
   PubMed Web of Science ®Google Scholar
• Kowalec K, McKay KA, Patten SB, et al. Comorbidity increases the risk of relapse in multiple sclerosis: a prospective study. Neurology. 2017;89(24):2455–2461.
   PubMed Web of Science ®Google Scholar
• Salter A, Kowalec K, Fitzgerald KC, et al. Comorbidity is associated with disease activity in MS: findings from the CombiRx trial. Neurology. 2020;95(5):e446–e456.
   PubMed Web of Science ®Google Scholar
• Kalanie H, Harandi AA, Alidaei S, et al. Venous thrombosis in multiple sclerosis patients after high-dose intravenous methylprednisolone: the preventive effect of enoxaparin. Thrombosis. 2011;2011:785459.
   PubMedGoogle Scholar
• Dossi DE, Chaves H, Heck ES, et al. Effects of systolic blood pressure on brain integrity in multiple sclerosis. Front Neurol. 2018;9:487–487.
   PubMed Web of Science ®Google Scholar
• Kappus N, Weinstock-Guttman B, Hagemeier J, et al. Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016;87(2):181–187.
   PubMed Web of Science ®Google Scholar
• Farez MF, Fiol MP, Gaitán MI, et al. Sodium intake is associated with increased disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatr. 2015;86(1):26–31.
   PubMed Web of Science ®Google Scholar
• Tun NN, Arunagirinathan G, Munshi SK, et al. Diabetes mellitus and stroke: a clinical update. World J Diabetes. 2017;8(6):235–248.
   PubMed Web of Science ®Google Scholar
• Zöller B, Li X, Sundquist J, et al. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet. 2012;379(9812):244–249.
   PubMed Web of Science ®Google Scholar
• Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost. 2006;4(11):2377–2383.
   PubMed Web of Science ®Google Scholar
• Koudriavtseva T, Plantone D, Renna R, et al. Interferon-β therapy and risk of thrombocytopenia in multiple sclerosis patients. Neurol Sci. 2015;36(12):2263–2268.
   PubMed Web of Science ®Google Scholar
• Jy W, Horstman LL, Arce M, et al. Clinical significance of platelet microparticles in autoimmune thrombocytopenias. J Lab Clin Med. 1992;119(4):334–345.
   PubMed Web of Science ®Google Scholar
• Rosso M, Chitnis T. Association between cigarette smoking and multiple sclerosis: a review. JAMA Neurol. 2020;77(2):245–253.
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Weinstock-Guttman B, Hashmi K, et al. Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology. 2009;73(7):504–510.
   PubMed Web of Science ®Google Scholar
• Degelman ML, Herman KM. Smoking and multiple sclerosis: a systematic review and meta-analysis using the bradford hill criteria for causation. Mult Scler Relat Disord. 2017;17:207–216.
   PubMed Web of Science ®Google Scholar
• Sundström P, Nyström L. Smoking worsens the prognosis in multiple sclerosis. Mult Scler. 2008;14(8):1031–1035.
   PubMed Web of Science ®Google Scholar
• Petersen ER, Oturai AB, Koch-Henriksen N, et al. Smoking affects the interferon beta treatment response in multiple sclerosis. Neurology. 2018;90(7):e593–e600.
   PubMed Web of Science ®Google Scholar
• Petersen ER, Søndergaard HB, Laursen JH, et al. Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis. Mult Scler. 2019;25(9):1298–1305.
   PubMed Web of Science ®Google Scholar
• Hersh CM, Harris H, Ayers M, et al. Effect of tobacco use on disease activity and DMT discontinuation in multiple sclerosis patients treated with dimethyl fumarate or fingolimod. Mult Scler J Exp Transl Clin. 2020;6(4):2055217320959815.
   Google Scholar
• Dalgas U, Stenager E. Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis? Ther Adv Neurol Disord. 2012;5(2):81–95.
   PubMed Web of Science ®Google Scholar
• Bovill EG, van der Vliet A. Venous valvular stasis-associated hypoxia and thrombosis: what is the link? Annu Rev Physiol. 2011;73:527–545.
   PubMed Web of Science ®Google Scholar
• Ranadive SM, Yan H, Weikert M, et al. Vascular dysfunction and physical activity in multiple sclerosis. Med Sci Sports Exerc. 2012;44(2):238–243.
   PubMed Web of Science ®Google Scholar
• Mokry LE, Ross S, Ahmad OS, et al. Vitamin D and risk of multiple sclerosis: a mendelian randomization study. PLoS Med. 2015;12(8):e1001866.
   PubMed Web of Science ®Google Scholar
• Simon KC, Munger KL, Ascherio A. Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics. Curr Opin Neurol. 2012;25(3):246–251.
   PubMed Web of Science ®Google Scholar
• Tzartos JS, Khan G, Vossenkamper A, et al. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology. 2012;78(1):15–23.
   PubMed Web of Science ®Google Scholar
• Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol. 2006;59(3):499–503.
   PubMed Web of Science ®Google Scholar
• Oliveira SR, Simão ANC, Alfieri DF, et al. Vitamin D deficiency is associated with disability and disease progression in multiple sclerosis patients independently of oxidative and nitrosative stress. J Neurol Sci. 2017;381:213–219.
   PubMed Web of Science ®Google Scholar
• Alfieri DF, Lehmann MF, Oliveira SR, et al. Vitamin D deficiency is associated with acute ischemic stroke, C-reactive protein, and short-term outcome. Metab Brain Dis. 2017;32(2):493–502.
   PubMed Web of Science ®Google Scholar
• Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol. 2007;61(4):288–299.
   PubMed Web of Science ®Google Scholar
• Nørgaard M, Nielsen RB, Jacobsen JB, et al. Use of penicillin and other antibiotics and risk of multiple sclerosis: a population-based case-control study. Am J Epidemiol. 2011;174(8):945–948.
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340(2):115–126.
   PubMed Web of Science ®Google Scholar
• Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med. 2000;343(13):938–952.
   PubMed Web of Science ®Google Scholar
• Serafini B, Rosicarelli B, Veroni C, et al. Epstein-Barr virus-specific CD8 T cells selectively infiltrate the brain in multiple sclerosis and interact locally with virus-infected cells: clue for a virus-driven immunopathological mechanism. J Virol. 2019;93(24):e00980–19.
   PubMed Web of Science ®Google Scholar
• Yarlagadda K, Ma N, Doré S. Vitamin D and stroke: effects on incidence, severity, and outcome and the potential benefits of supplementation. Front Neurol. 2020;11:384.
   PubMed Web of Science ®Google Scholar
• Ghaderi S, Berg-Hansen P, Bakken IJ, et al. Hospitalization following influenza infection and pandemic vaccination in multiple sclerosis patients: a nationwide population-based registry study from Norway. Eur J Epidemiol. 2020;35(4):355–362.
   PubMed Web of Science ®Google Scholar
• Goodin DS, Corwin M, Kaufman D, et al. Causes of death among commercially insured multiple sclerosis patients in the United States. PLoS One. 2014;9(8):e105207.
   PubMed Web of Science ®Google Scholar
• Kingwell E, van der Kop M, Zhao Y, et al. Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada. J Neurol Neurosurg Psychiatry. 2012;83(1):61–66.
   PubMed Web of Science ®Google Scholar
• Harandi AA, Harandi AA, Pakdaman H, et al. Vitamin D and multiple sclerosis. Iran J Neurol. 2014;13(1):1–6.
   PubMedGoogle Scholar
• Kienreich K, Tomaschitz A, Verheyen N, et al. Vitamin D and cardiovascular disease. Nutrients. 2013;5(8):3005–3021.
   PubMed Web of Science ®Google Scholar
• Schneider AL, Lutsey PL, Selvin E, et al. Vitamin D, vitamin D binding protein gene polymorphisms, race and risk of incident stroke: the atherosclerosis risk in communities (ARIC) study. Eur J Neurol. 2015;22(8):1220–1227.
   PubMed Web of Science ®Google Scholar
• Chowdhury R, Stevens S, Ward H, et al. Circulating vitamin D, calcium and risk of cerebrovascular disease: a systematic review and Meta-analysis. Eur J Epidemiol. 2012;27(8):581–591.
   PubMed Web of Science ®Google Scholar
• Miclea A, Bagnoud M, Chan A, et al. A brief review of the effects of vitamin D on multiple sclerosis. Front Immunol. 2020;11:781. (
   PubMedGoogle Scholar
• D’Angelo C, Franch O, Fernández-Paredes L, et al. Antiphospholipid antibodies overlapping in isolated neurological syndrome and multiple sclerosis: Neurobiological insights and diagnostic challenges. Front Cell Neurosci. 2019;13:107. (
   PubMed Web of Science ®Google Scholar
• Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306.
   PubMed Web of Science ®Google Scholar
• Martins FF, Campos TML. Evaluation of frequency, clinical correlation, and antibodies confirmation profile in patients with suspected antiphospholipid syndrome. TH Open. 2021;5(4):e470–e478.
   PubMedGoogle Scholar
• Velásquez M, Rojas M, Abrahams VM, et al. Mechanisms of endothelial dysfunction in antiphospholipid syndrome: Association with clinical manifestations. Front Physiol. 2018;9:1840–1840.
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Crowther M, Branch W, et al. Antiphospholipid syndrome. Lancet. 2010;376(9751):1498–1509.
   PubMed Web of Science ®Google Scholar
• Muscal E, Brey RL. Neurological manifestations of the antiphospholipid syndrome: risk assessments and evidence-based medicine. Int J Clin Pract. 2007;61(9):1561–1568.
   PubMed Web of Science ®Google Scholar
• Arboix A, Jiménez C, Massons J, et al. Hematological disorders: a commonly unrecognized cause of acute stroke. Expert Rev Hematol. 2016;9(9):891–901.
   PubMed Web of Science ®Google Scholar
• Fernández-Fernández FJ, Rivera-Gallego A, de la Fuente-Aguado J, et al. Antiphospholipid syndrome mimicking multiple sclerosis in two patients. Eur J Intern Med. 2006;17(7):500–502.
   PubMed Web of Science ®Google Scholar
• Fleetwood T, Cantello R, Comi C. Antiphospholipid syndrome and the neurologist: from pathogenesis to therapy. Front Neurol. 2018;9:1001.
   PubMed Web of Science ®Google Scholar
• Ahbeddou N, Ait Ben Haddou E, Hammi S, et al. [Multiple sclerosis associated with antiphospholipid syndrome: diagnostic and therapeutic difficulties]. Rev Neurol (Paris). 2012;168(1):65–69.
   PubMed Web of Science ®Google Scholar
• Cuadrado MJ, Khamashta MA, Ballesteros A, et al. Can neurologic manifestations of hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine. 2000;79(1):57–68.
   PubMed Web of Science ®Google Scholar
• Ferreira S, D’Cruz DP, Hughes GR. Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand? Rheumatology (Oxford). 2005;44(4):434–442.
   PubMed Web of Science ®Google Scholar
• Miesbach W. Neurologic symptoms as a feature of the antiphospholipid syndrome. Semin Thromb Hemost. 2008;34(3):286–289.
   PubMed Web of Science ®Google Scholar
• Stosic M, Ambrus J, Garg N, et al. MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis. J Neurol. 2010;257(1):63–71.
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y, Twig G, Katz U, et al. Autoantibody explosion in antiphospholipid syndrome. J Autoimmun. 2008;30(1-2):74–83.
   PubMed Web of Science ®Google Scholar
• Devreese KMJ. How to interpret antiphospholipid laboratory tests. Curr Rheumatol Rep. 2020;22(8):38.
   PubMed Web of Science ®Google Scholar
• Karussis D, Leker RR, Ashkenazi A, et al. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? Ann Neurol. 1998;44(4):629–634.
   PubMed Web of Science ®Google Scholar
• Bidot CJ, Horstman LL, Jy W, et al. Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study. BMC Neurol. 2007;7(1):36–36.
   PubMedGoogle Scholar
• Heinzlef O, Weill B, Johanet C, et al. Anticardiolipin antibodies in patients with multiple sclerosis do not represent a subgroup of patients according to clinical, familial, and biological characteristics. J Neurol Neurosurg Psychiatry. 2002;72(5):647–649.
   PubMed Web of Science ®Google Scholar
• Filippidou N, Krashias G, Pericleous C, et al. The association between IgG and IgM antibodies against cardiolipin, β2-glycoprotein I and domain I of β2-glycoprotein I with disease profile in patients with multiple sclerosis. Mol Immunol. 2016;75:161–167.
   PubMed Web of Science ®Google Scholar
• Garg N, Zivadinov R, Ramanathan M, et al. Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. J Neuroimmunol. 2007;187(1-2):159–165.
   PubMed Web of Science ®Google Scholar
• Grönwall C, Vas J, Silverman G. Protective roles of natural IgM antibodies. Front Immunol. 2012;3(66):66.
   PubMedGoogle Scholar
• Koudriavtseva T, D’Agosto G, Mandoj C, et al. High frequency of antiphospholipid antibodies in relapse of multiple sclerosis: a possible indicator of inflammatory-thrombotic processes. Neurol Sci. 2014;35(11):1737–1741.
   PubMed Web of Science ®Google Scholar
• Liedorp M, Sanchez E, van Hoogstraten IMW, et al. No evidence of misdiagnosis in patients with multiple sclerosis and repeated positive anticardiolipin antibody testing based on magnetic resonance imaging and long term follow-up. J Neurol Neurosurg Psychiatry. 2007;78(10):1146–1148.
   PubMed Web of Science ®Google Scholar
• Mandoj C, Renna R, Plantone D, et al. Anti-annexin antibodies, cholesterol levels and disability in multiple sclerosis. Neurosci Lett. 2015;606:156–160.
   PubMed Web of Science ®Google Scholar
• Merashli M, Alves JD, Gentile F, et al. Relevance of antiphospholipid antibodies in multiple sclerosis: a systematic review and Meta analysis. Semin Arthritis Rheum. 2017;46(6):810–818.
   PubMed Web of Science ®Google Scholar
• Urbanus RT, Siegerink B, Roest M, et al. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol. 2009;8(11):998–1005.
   PubMed Web of Science ®Google Scholar
• de Groot PG, Lutters B, Derksen RH, et al. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost. 2005;3(9):1993–1997.
   PubMed Web of Science ®Google Scholar
• Uthman I, Noureldine MHA, Berjawi A, et al. Hughes syndrome and multiple sclerosis. Lupus. 2015;24(2):115–121.
   PubMed Web of Science ®Google Scholar
• Shor DB, Weiss GA, Barzilai O, et al. Prevalence of classic and Non-Classic antiphospholipid antibodies in multiple sclerosis. Isr Med Assoc J. 2015;17(9):559–562.
   PubMed Web of Science ®Google Scholar
• Szmyrka-Kaczmarek M, Pokryszko-Dragan A, Pawlik B, et al. Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis. Lupus. 2012;21(4):412–420.
   PubMed Web of Science ®Google Scholar
• Baraczka K, Lakos G, Sipka S. Immunoserological changes in the cerebro-spinal fluid and serum in systemic lupus erythematosus patients with demyelinating syndrome and multiple sclerosis. Acta Neurol Scand. 2002;105(5):378–383.
   PubMed Web of Science ®Google Scholar
• Carrillo-Mora P, González-Villalva A. Clinical characteristics and presence of antiphospholipid antibodies (anticardiolipin-beta2GP-1) cerebrospinal fluid and serum of in a series of patients with multiple sclerosis in Mexico. ]Neurologia. 2010;25(2):71–77. [
   PubMed Web of Science ®Google Scholar
• Rombos A, Evangelopoulou-Katsiri E, Leventakou A, et al. Serum IgG and IgM anticardiolipin antibodies in neurological diseases. Acta Neurol Scand. 1990;81(3):243–245.
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Ramanathan M, Ambrus J, et al. Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study. Neurol Res. 2012;34(8):761–769.
   PubMed Web of Science ®Google Scholar
• Merashli M, Noureldine MH, Uthman I, et al. Antiphospholipid syndrome: an update. Eur J Clin Invest. 2015;45(6):653–662.
   PubMed Web of Science ®Google Scholar
• Pierangeli SS, Chen PP, González EB. Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms. Curr Opin Hematol. 2006;13(5):366–375.
   PubMed Web of Science ®Google Scholar
• Shojaie M, Sotoodah A, Roozmeh S, et al. Annexin V and anti-Annexin V antibodies: two interesting aspects in acute myocardial infarction. Thromb J. 2009;7(1):13.
   PubMedGoogle Scholar
• Colamatteo A, Maggioli E, Azevedo Loiola R, et al. Reduced annexin A1 expression associates with disease severity and inflammation in multiple sclerosis patients. J Immunol. 2019;203(7):1753–1765.
   PubMed Web of Science ®Google Scholar
• Tavazzi B, Batocchi AP, Amorini AM, et al. Serum metabolic profile in multiple sclerosis patients. Mult Scler Int. 2011;2011:167156.
   PubMedGoogle Scholar
• Ferreira KPZ, Oliveira SR, Kallaur AP, et al. Disease progression and oxidative stress are associated with higher serum ferritin levels in patients with multiple sclerosis. J Neurol Sci. 2017;373:236–241.
   PubMed Web of Science ®Google Scholar
• Oliveira SR, Kallaur AP, Lopes J, et al. Insulin resistance, atherogenicity, and iron metabolism in multiple sclerosis with and without depression: Associations with inflammatory and oxidative stress biomarkers and uric acid. Psychiatry Res. 2017;250:113–120.
   PubMed Web of Science ®Google Scholar
• van der DL, Grobbee DE, Roest M, et al. Serum ferritin is a risk factor for stroke in postmenopausal women. Stroke. 2005;36(8):1637–1641.
   PubMed Web of Science ®Google Scholar
• LeVine SM, Lynch SG, Ou CN, et al. Ferritin, transferrin and iron concentrations in the cerebrospinal fluid of multiple sclerosis patients. Brain Res. 1999;821(2):511–515.
   PubMed Web of Science ®Google Scholar
• Petzold A, Eikelenboom MJ, Gveric D, et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain. 2002;125(7):1462–1473.
   PubMedGoogle Scholar
• Sfagos C, Makis AC, Chaidos A, et al. Serum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patients. Mult Scler. 2005;11(3):272–275.
   PubMed Web of Science ®Google Scholar
• Worthington V, Killestein J, Eikelenboom MJ, et al. Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency. Neurology. 2010;75(18):1617–1622.
   PubMed Web of Science ®Google Scholar
• Adamczyk B, Adamczyk-Sowa M. New insights into the role of oxidative stress mechanisms in the pathophysiology and treatment of multiple sclerosis. Oxid Med Cell Longev. 2016;2016:1973834.
   PubMed Web of Science ®Google Scholar
• Knyszyńska A, Radecka A, Zabielska P, et al. The role of iron metabolism in fatigue, depression, and quality of life in multiple sclerosis patients. Int J Environ Res Public Health. 2020;17(18):6818.
   PubMed Web of Science ®Google Scholar
• Wang Q, Wen X, Kong J. Recent progress on uric acid detection: a review. Crit Rev Anal Chem. 2020;50(4):359–375.
   PubMed Web of Science ®Google Scholar
• Peng F, Zhang B, Zhong X, et al. Serum uric acid levels of patients with multiple sclerosis and other neurological diseases. Mult Scler. 2008;14(2):188–196.
   PubMedGoogle Scholar
• Zhong C, Zhong X, Xu T, et al. Sex-Specific relationship between serum uric acid and risk of stroke: a Dose-Response Meta-Analysis of prospective studies. J Am Heart Assoc. 2017;6(4):e005042.
   Web of Science ®Google Scholar
• Wang Y-F, Li J-X, Sun X-S, et al. High serum uric acid levels are a protective factor against unfavourable neurological functional outcome in patients with ischaemic stroke. J Int Med Res. 2018;46(5):1826–1838.
   PubMed Web of Science ®Google Scholar
• Tariq MA, Shamim SA, Rana KF, et al. Serum uric Acid - Risk factor for acute ischemic stroke and poor outcomes. Cureus. 2019;11(10):e6007.
   PubMed Web of Science ®Google Scholar
• Toncev G, Milicic B, Toncev S, et al. Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002;9(3):221–226.
   PubMed Web of Science ®Google Scholar
• Toncev G, Vesic K, Aleksic D, et al. Higher serum uric acid levels in multiple sclerosis patients after longterm interferon beta treatment. Serb J Experim Clin Res. 2017;18(3):227–230.
   Google Scholar
• Guerrero AL, Gutiérrez F, Iglesias F, et al. Serum uric acid levels in multiple sclerosis patients inversely correlate with disability. Neurol Sci. 2011;32(2):347–350.
   PubMed Web of Science ®Google Scholar
• Rentzos M, Nikolaou C, Anagnostouli M, et al. Serum uric acid and multiple sclerosis. Clin Neurol Neurosurg. 2006;108(6):527–531.
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Tortorella C, Iaffaldano P, et al. Low serum urate levels are associated to female gender in multiple sclerosis patients. PLoS One. 2012;7(7):e40608-e40608.
   Web of Science ®Google Scholar
• Massa J, O’Reilly E, Munger KL, et al. Serum uric acid and risk of multiple sclerosis. J Neurol. 2009;256(10):1643–1648.
   PubMed Web of Science ®Google Scholar
• Koch M, De Keyser J. Uric acid in multiple sclerosis. Neurol Res. 2006;28(3):316–319.
   PubMed Web of Science ®Google Scholar
• Liu B, Shen Y, Xiao K, et al. Serum uric acid levels in patients with multiple sclerosis: a meta-analysis. Neurol Res. 2012;34(2):163–171.
   PubMed Web of Science ®Google Scholar
• Pakpoor J, Seminog OO, Ramagopalan SV, et al. Clinical associations between gout and multiple sclerosis, parkinson’s disease and motor neuron disease: record-linkage studies. BMC Neurol. 2015;15:16.
   PubMed Web of Science ®Google Scholar
• Moccia M, Lanzillo R, Palladino R, et al. Uric acid: a potential biomarker of multiple sclerosis and of its disability. Clin Chem Lab Med (CCLM). 2015;53(5):753–759.
   Google Scholar
• Markowitz CE, Spitsin S, Zimmerman V, et al. The treatment of multiple sclerosis with inosine. J Altern Complement Med. 2009;15(6):619–625.
   PubMedGoogle Scholar
• Gonsette RE, Sindic C, D’Hooghe MB, et al. Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of inosine and interferon β in relapsing- remitting multiple sclerosis (ASIIMS) trial. Mult Scler. 2010;16(4):455–462.
   PubMed Web of Science ®Google Scholar
• Spitsin S, Markowitz CE, Zimmerman V, et al. Modulation of serum uric acid levels by inosine in patients with multiple sclerosis does not affect blood pressure. J Hum Hypertens. 2010;24(5):359–362.
   PubMed Web of Science ®Google Scholar
• Gauthier GM, Keevil JG, McBride PE. The association of homocysteine and coronary artery disease. Clin Cardiol. 2003;26(12):563–568.
   PubMed Web of Science ®Google Scholar
• Ansari R, Mahta A, Mallack E, et al. Hyperhomocysteinemia and neurologic disorders: a review. J Clin Neurol. 2014;10(4):281–288.
   PubMed Web of Science ®Google Scholar
• Ho PI, Ortiz D, Rogers E, et al. Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res. 2002;70(5):694–702.
   PubMed Web of Science ®Google Scholar
• Teunissen CE, Killestein J, Kragt JJ, et al. Serum homocysteine levels in relation to clinical progression in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2008;79(12):1349–1353.
   PubMed Web of Science ®Google Scholar
• Kararizou E, Paraskevas G, Triantafyllou N, et al. Plasma homocysteine levels in patients with multiple sclerosis in the greek population. J Chin Med Assoc. 2013;76(11):611–614.
   PubMed Web of Science ®Google Scholar
• Triantafyllou N, Evangelopoulos M-E, Kimiskidis VK, et al. Increased plasma homocysteine levels in patients with multiple sclerosis and depression. Ann Gen Psychiatry. 2008;7(1):17–17.
   PubMedGoogle Scholar
• Goodkin DE, Jacobsen DW, Galvez N, et al. Serum cobalamin deficiency is uncommon in multiple sclerosis. Arch Neurol. 1994;51(11):1110–1114.
   PubMedGoogle Scholar
• Vrethem M, Mattsson E, Hebelka H, et al. Increased plasma homocysteine levels without signs of vitamin B12 deficiency in patients with multiple sclerosis assessed by blood and cerebrospinal fluid homocysteine and methylmalonic acid. Mult Scler. 2003;9(3):239–245.
   PubMed Web of Science ®Google Scholar
• Ramsaransing GS, Fokkema MR, Teelken A, et al. Plasma homocysteine levels in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2006;77(2):189–192.
   PubMed Web of Science ®Google Scholar
• Río J, Montalban J, Tintoré M, et al. Serum homocysteine levels in multiple sclerosis. Arch Neurol. 1994;51(12):1181.
   PubMedGoogle Scholar
• Bala MM, Celinska-Lowenhoff M, Szot W, et al. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. Cochrane Database Syst Rev. 2020;10:CD012169.
   PubMedGoogle Scholar
• Dardiotis E, Arseniou S, Sokratous M, et al. Vitamin B12, folate, and homocysteine levels and multiple sclerosis: a Meta-analysis. Mult Scler Relat Disord. 2017;17:190–197.
   PubMed Web of Science ®Google Scholar
• Zhu Y, He ZY, Liu HN. Meta-analysis of the relationship between homocysteine, vitamin B12, folate, and multiple sclerosis. J Clin Neurosci. 2011;18(7):933–938.
   PubMed Web of Science ®Google Scholar
• Kocer B, Engur S, Ak F, et al. Serum vitamin B12, folate, and homocysteine levels and their association with clinical and electrophysiological parameters in multiple sclerosis. J Clin Neurosci. 2009;16(3):399–403.
   PubMed Web of Science ®Google Scholar
• Dubchenko E, Ivanov A, Spirina N, et al. Hyperhomocysteinemia and endothelial dysfunction in multiple sclerosis. Brain Sci. 2020;10(9):637.
   PubMed Web of Science ®Google Scholar
• Aksungar FB, Topkaya AE, Yildiz Z, et al. Coagulation status and biochemical and inflammatory markers in multiple sclerosis. J Clin Neurosci. 2008;15(4):393–397.
   PubMed Web of Science ®Google Scholar
• Oliveira SR, Flauzino T, Sabino BS, et al. Elevated plasma homocysteine levels are associated with disability progression in patients with multiple sclerosis. Metab Brain Dis. 2018;33(5):1393–1399.
   PubMed Web of Science ®Google Scholar
• D’Haeseleer M, Beelen R, Fierens Y, et al. Cerebral hypoperfusion in multiple sclerosis is reversible and mediated by endothelin-1. Proc Natl Acad Sci U S A. 2013;110(14):5654–5658.
   PubMed Web of Science ®Google Scholar
• Hostenbach S, Raeymaekers H, Van Schuerbeek P, et al. The role of cerebral hypoperfusion in multiple sclerosis (ROCHIMS) trial in multiple sclerosis: Insights from negative Results. Front Neurol. 2020;11:674.
   PubMed Web of Science ®Google Scholar
• Ziv I, Fleminger G, Djaldetti R, et al. Increased plasma endothelin-1 in acute ischemic stroke. Stroke. 1992;23(7):1014–1016.
   PubMed Web of Science ®Google Scholar
• Abdel Naseer M, Rabah AM, Rashed LA, et al. Glutamate and nitric oxide as biomarkers for disease activity in patients with multiple sclerosis. Mult Scler Relat Disord. 2020;38:101873.
   PubMed Web of Science ®Google Scholar
• Ibragic S, Sofic E, Suljic E, et al. Serum nitric oxide concentrations in patients with multiple sclerosis and patients with epilepsy. J Neural Transm (Vienna). 2012;119(1):7–11.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Sáinz Mdel C, Sánchez-Ramón S, de Andrés C, et al. Th1/Th2 cytokine balance and nitric oxide in cerebrospinal fluid and serum from patients with multiple sclerosis. Eur Cytokine Netw. 2002;13(1):110–114.
   PubMed Web of Science ®Google Scholar
• Smith K, Lassmann H. The role of nitric oxide in multiple sclerosis. Lancet Neurol. 2002;1(4):232–241.
   PubMed Web of Science ®Google Scholar
• Subedi L, Gaire BP, Parveen A, et al. Nitric oxide as a target for phytochemicals in anti-Neuroinflammatory prevention therapy. Int J Mol Sci. 2021;22(9):4771.
   Web of Science ®Google Scholar
• Hallwirth F. Serum nitric oxide is increased in untreated multiple sclerosis patients. 27 Oct 2017. ECTRIMS Online Library; 200778;Poster 1123.
   Google Scholar
• Castillo J, Rama R, Dávalos A. Nitric oxide–related brain damage in acute ischemic stroke. Stroke. 2000;31(4):852–857.
   PubMed Web of Science ®Google Scholar
• Al Gawwam G, Sharquie IK. Serum glutamate is a predictor for the diagnosis of multiple sclerosis. SciWorldJ. 2017;2017:9320802.
   Google Scholar
• Lan M, Tang X, Zhang J, et al. Insights in pathogenesis of multiple sclerosis: nitric oxide may induce mitochondrial dysfunction of oligodendrocytes. Rev Neurosci. 2018;29(1):39–53.
   PubMed Web of Science ®Google Scholar
• Chen ZQ, Mou RT, Feng DX, et al. The role of nitric oxide in stroke. Med Gas Res. 2017;7(3):194–203.
   PubMed Web of Science ®Google Scholar
• Steensig K, Olesen Kevin KW, Thim T, et al. CAD is an independent risk factor for stroke among patients with Atrial Fibrillation. J Am Coll Cardiol. 2018;72(20):2540–2542.
   PubMed Web of Science ®Google Scholar
• De Raedt S, De Vos A, De Keyser J. Autonomic dysfunction in acute ischemic stroke: an underexplored therapeutic area? J Neurol Sci. 2015;348(1-2):24–34.
   PubMed Web of Science ®Google Scholar
• Jimenez-Ruiz A, Racosta JM, Kimpinski K, et al. Cardiovascular autonomic dysfunction after stroke. Neurol Sci. 2021;42(5):1751–1758.
   PubMed Web of Science ®Google Scholar
• Brook RD, Julius S. Autonomic imbalance, hypertension, and cardiovascular risk. Am J Hypertens. 2000;13(6 Pt 2):112s–1122. s.
   PubMed Web of Science ®Google Scholar
• Sternberg Z. Impaired neurovisceral integration of cardiovascular modulation contributes to multiple sclerosis morbidities. Mol Neurobiol. 2017;54(1):362–374.
   PubMed Web of Science ®Google Scholar
• Flachenecker P, Reiners K, Krauser M, et al. Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability. Mult Scler. 2001;7(5):327–334.
   PubMedGoogle Scholar
• Nasseri K, Uitdehaag BMJ, van Walderveen MAA, et al. Cardiovascular autonomic function in patients with relapsing remitting multiple sclerosis: a new surrogate marker of disease evolution? Eur J Neurol. 1999;6(1):29–33.
   PubMed Web of Science ®Google Scholar
• Racosta JM, Kimpinski K. Autonomic dysfunction, immune regulation, and multiple sclerosis. Clin Auton Res. 2016;26(1):23–31.
   PubMed Web of Science ®Google Scholar
• Shirbani F, Barin E, Lee YC, et al. Characterisation of cardiac autonomic function in multiple sclerosis based on spontaneous changes of heart rate and blood pressure. Mult Scler Relat Disord. 2018;22:120–127.
   PubMed Web of Science ®Google Scholar
• Findling O, Hauer L, Pezawas T, et al. Cardiac autonomic dysfunction in multiple sclerosis: a systematic review of current knowledge and impact of immunotherapies. J Clin Med. 2020;9(2):335.
   PubMed Web of Science ®Google Scholar
• Pascolo L, Gianoncelli A, Rizzardi C, et al. Calcium micro-depositions in jugular truncular venous malformations revealed by synchrotron-based XRF imaging. Sci Rep. 2014;4:6540.
   PubMed Web of Science ®Google Scholar
• Zamboni P, Tisato V, Menegatti E, et al. Ultrastructure of internal jugular vein defective valves. Phlebology. 2015;30(9):644–647.
   PubMed Web of Science ®Google Scholar
• Coen M, Menegatti E, Salvi F, et al. Altered collagen expression in jugular veins in multiple sclerosis. Cardiovasc Pathol. 2013;22(1):33–38.
   PubMed Web of Science ®Google Scholar
• Racosta JM, Sposato LA, Morrow SA, et al. Cardiovascular autonomic dysfunction in multiple sclerosis: a meta-analysis. Mult Scler Relat Disord. 2015;4(2):104–111.
   PubMed Web of Science ®Google Scholar
• Simula S, Laitinen T, Laitinen TM, et al. Effect of fingolimod on cardiac autonomic regulation in patients with multiple sclerosis. Mult Scler. 2016;22(8):1080–1085.
   PubMed Web of Science ®Google Scholar
• Simula S, Laitinen TP, Laitinen TM, et al. Heart rate variability predicts the magnitude of heart rate decrease after fingolimod initiation. Mult Scler Relat Disord. 2016;10:86–89.
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(6):545–556.
   PubMed Web of Science ®Google Scholar
• Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355(11):1124–1140.
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402–415.
   PubMed Web of Science ®Google Scholar
• Kappos L, O’Connor P, Radue EW, et al. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology. 2015;84(15):1582–1591.
   PubMed Web of Science ®Google Scholar
• Kappos L, Cohen J, Collins W, et al. Fingolimod in relapsing multiple sclerosis: an integrated analysis of safety findings. Mult Scler Relat Disord. 2014;3(4):494–504.
   PubMed Web of Science ®Google Scholar
• DiMarco JP, O’Connor P, Cohen JA, et al. First-dose effects of fingolimod: Pooled safety data from three phase 3 studies. Mult Scler Relat Disord. 2014;3(5):629–638.
   PubMed Web of Science ®Google Scholar
• Gold R, Comi G, Palace J, FIRST Study Investigators, et al. Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. J Neurol. 2014;261(2):267–276.
   PubMed Web of Science ®Google Scholar
• Laroni A, Brogi D, Morra VB, EAP Investigators, et al. Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. BMC Neurol. 2014;14:65.
   PubMed Web of Science ®Google Scholar
• Limmroth V, Ziemssen T, Lang M, et al. Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study. BMC Neurol. 2017;17(1):11.
   PubMed Web of Science ®Google Scholar
• Ontaneda D, Hara-Cleaver C, Rudick RA, et al. Early tolerability and safety of fingolimod in clinical practice. J Neurol Sci. 2012;323(1-2):167–172.
   PubMed Web of Science ®Google Scholar
• Fragoso YD, Arruda CC, Arruda WO, et al. The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis. Arq Neuropsiquiatr. 2014;72(9):712–714.
   PubMed Web of Science ®Google Scholar
• Paolicelli D, Manni A, Direnzo V, et al. Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: a postmarketing study. J Clin Pharmacol. 2015;55(10):1131–1136.
   PubMed Web of Science ®Google Scholar
• Castillo-Trivino T, Lopetegui I, Alarcón-Duque JA, et al. Ventricular tachycardia on chronic fingolimod treatment for multiple sclerosis. J Neurol Neurosurg Psychiatry. 2015;86(8):931–932.
   PubMed Web of Science ®Google Scholar
• Kocyigit D, Yalcin MU, Gurses KM, et al. Are there any clinical and electrocardiographic predictors of heart rate reduction in relapsing- remitting multiple sclerosis patients treated with fingolimod? Mult Scler Relat Disord. 2019;27:276–280.
   PubMed Web of Science ®Google Scholar
• Rosini JM, Rajasimhan S, Fellows SE, et al. Delayed cardiac dysrhythmias after fingolimod administration. Am J Emerg Med. 2015;33(7):987.e1–987.e3.
   PubMed Web of Science ®Google Scholar
• Espinosa PS, Berger JR. Delayed fingolimod-associated asystole. Mult Scler. 2011;17(11):1387–1389.
   PubMed Web of Science ®Google Scholar
• Lindsey JW, Haden-Pinneri K, Memon NB, et al. Sudden unexpected death on fingolimod. Mult Scler. 2012;18(10):1507–1508.
   PubMed Web of Science ®Google Scholar
• Mori M. Lethal arrhythmia due to fingolimod, a S1P receptor modulator: are we overestimating or underestimating? J Neurol Neurosurg Psychiatry. 2015;86(8):823.
   PubMed Web of Science ®Google Scholar
• Racca V, Rovaris M, Cavarretta R, et al. Acute fingolimod effects on baroreflex and cardiovascular autonomic control in multiple Sclerosis. J Cent Nerv Syst Dis. 2019;11:1179573519849945.
   Web of Science ®Google Scholar
• Hilz MJ, Wang R, de Rojas Leal C, et al. Fingolimod initiation in multiple sclerosis patients is associated with potential beneficial cardiovascular autonomic effects. Ther Adv Neurol Disord. 2017;10(4):191–209.
   PubMed Web of Science ®Google Scholar
• Olindo S, Guillon B, Helias J, et al. Decrease in heart ventricular ejection fraction during multiple sclerosis. Eur J Neurol. 2002;9(3):287–291.
   PubMed Web of Science ®Google Scholar
• Yagi Y, Nakamura Y, Kitahara K, et al. Analysis of onset mechanisms of a sphingosine 1-Phosphate receptor modulator Fingolimod-Induced atrioventricular conduction block and QT-Interval prolongation. Toxicol Appl Pharmacol. 2014;281(1):39–47.
   PubMed Web of Science ®Google Scholar
• Camm J, Hla T, Bakshi R, et al. Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications. Am Heart J. 2014;168(5):632–644.
   PubMed Web of Science ®Google Scholar
• Limmroth V, Ziemssen T, Kleiter I, et al. A comprehensive monitoring study on electrocardiographic assessments and cardiac events after fingolimod first Dose-Possible predictors of cardiac outcomes. Front Neurol. 2020;11:818.
   PubMedGoogle Scholar
• Vanoli E, Montano N, De Angelis G, et al. Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod. J Neurol Sci. 2019;405:116423.
   PubMed Web of Science ®Google Scholar
• Tsai HC, Han MH. Sphingosine-1-Phosphate (S1P) and S1P signaling pathway: Therapeutic targets in autoimmunity and inflammation. Drugs. 2016;76(11):1067–1079.
   PubMed Web of Science ®Google Scholar
• Spielman LJ, Gibson DL, Klegeris A. Unhealthy gut, unhealthy brain: the role of the intestinal microbiota in neurodegenerative diseases. Neurochem Int. 2018;120:149–163.
   PubMed Web of Science ®Google Scholar
• Yamashiro K, Kurita N, Urabe T, et al. Role of the gut microbiota in stroke pathogenesis and potential therapeutic implications. Ann Nutr Metab. 2021;77(Suppl. 2):36–39.)
   PubMed Web of Science ®Google Scholar
• Tyler Patterson T, Grandhi R. Gut microbiota and neurologic diseases and injuries. Adv Exp Med Biol. 2020;1238:73–91.
   PubMed Web of Science ®Google Scholar
• Marrie RA, Cohen J, Stuve O, et al. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. Mult Scler. 2015;21(3):263–281.
   PubMed Web of Science ®Google Scholar
• Kasper L, Chitnis T, Avila M, et al. Exploring the role of the microbiome in multiple sclerosis. US Neurology. 2019;15(2):82.
   Google Scholar
• Dreikorn M, Milacic Z, Pavlovic V, et al. Immunotherapy of experimental and human stroke with agents approved for multiple sclerosis: a systematic review. Ther Adv Neurol Disord. 2018;11:1756286418770626.
   Web of Science ®Google Scholar
• Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: Report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777–788.
   PubMed Web of Science ®Google Scholar
• Ghezzi A. European and American guidelines for multiple sclerosis treatment. Neurol Ther. 2018;7(2):189–194.
   PubMedGoogle Scholar
• McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA. 2021;325(8):765–779.
   PubMed Web of Science ®Google Scholar
• Graf J, Aktas O, Rejdak K, et al. Monoclonal antibodies for multiple sclerosis: an update. BioDrugs. 2019;33(1):61–78.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Weinshenker BG. Disease modifying therapies for relapsing multiple sclerosis. BMJ. 2016;354:i3518.
   PubMed Web of Science ®Google Scholar
• Hillert J, Magyari M, Soelberg Sørensen P, et al. Treatment switching and discontinuation over 20 years in the big multiple sclerosis data network. Front Neurol. 2021;12(295):647811.
   PubMedGoogle Scholar
• Sternberg Z, Leung C, Sternberg D, et al. Disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis. Cardiovasc Ther. 2014;32(2):33–39.
   PubMed Web of Science ®Google Scholar
• Morra VB, Coppola G, Orefice G, et al. Interferon-beta treatment decreases cholesterol plasma levels in multiple sclerosis patients. Neurology. 2004;62(5):829–830.
   PubMed Web of Science ®Google Scholar
• Wijnands JMA, Zhu F, Kingwell E, et al. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study. J Neurol Neurosurg Psychiatry. 2018;89(10):1050–1056.
   PubMed Web of Science ®Google Scholar
• Yong KP, Kim HJ. Disease modifying therapies and infection risks in multiple sclerosis-a decision-making conundrum. Ann Transl Med. 2020;8(11):722.
   PubMed Web of Science ®Google Scholar
• Uher T, Fellows K, Horakova D, et al. Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients. J Lipid Res. 2017;58(2):403–411.
   PubMed Web of Science ®Google Scholar
• de Jong HJI, Kingwell E, Shirani A, British Columbia Multiple Sclerosis Clinic Neurologists, et al. Evaluating the safety of β-interferons in MS: a series of nested case-control studies. Neurology. 2017;88(24):2310–2320.
   PubMed Web of Science ®Google Scholar
• Blumenfeld Kan S, Staun-Ram E, Golan D, et al. HDL-cholesterol elevation associated with fingolimod and dimethyl fumarate therapies in multiple sclerosis. Mult Scler J Exp Transl Clin. 2019;5(4):2055217319882720.
   Google Scholar
• Förster M, Küry P, Aktas O, et al. Managing risks with immune therapies in multiple sclerosis. Drug Saf. 2019;42(5):633–647.
   PubMed Web of Science ®Google Scholar
• Baharnoori M, Gonzalez CT, Chua A, et al. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count. Mult Scler Relat Disord. 2018;20:51–57.
   PubMed Web of Science ®Google Scholar
• Azevedo CJ, Kutz C, Dix A, et al. Intracerebral haemorrhage during alemtuzumab administration. Lancet Neurol. 2019;18(4):329–331.
   PubMed Web of Science ®Google Scholar
• Alnahdi MA, Aljarba SI, Al Malik YM. Alemtuzumab-induced simultaneous onset of autoimmune haemolytic anaemia, alveolar haemorrhage, nephropathy, and stroke: a case report. Mult Scler Relat Disord. 2020;41:102141.
   PubMed Web of Science ®Google Scholar
• FDA. FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab). 2018. [cited 2021 07 July].
   Google Scholar
• Ravnborg M, Sørensen PS, Andersson M, et al. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurol. 2010;9(7):672–680.
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Mellgren SI, Svenningsson A, et al. NORdic trial of oral methylprednisolone as add-on therapy to interferon beta-1a for treatment of relapsing-remitting multiple sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol. 2009;8(6):519–529.
   PubMed Web of Science ®Google Scholar
• Sabidó M, Venkatesh S, Hayward B, et al. Subcutaneous interferon-β1a does not increase the risk of stroke in patients with multiple sclerosis: Analysis of pooled clinical trials and Post-Marketing surveillance. Adv Ther. 2018;35(11):2041–2053.
   PubMed Web of Science ®Google Scholar
• Dimopoulou D, Dimosiari A, Mandala E, et al. Autoimmune thrombotic thrombocytopenic purpura: Two rare cases associated with juvenile idiopathic arthritis and multiple sclerosis. Front Med (Lausanne). 2017;4:89.
   PubMed Web of Science ®Google Scholar
• Baghbanian SM, Moghadasi AN. Thrombotic microangiopathy associated with interferon-beta treatment in patients with multiple sclerosis. Iran J Neurol. 2018;17(2):89–90.
   PubMed Web of Science ®Google Scholar
• Nishio H, Tsukamoto T, Matsubara T, et al. Thrombotic microangiopathy caused by interferon β-1b for multiple sclerosis: a case report. CEN Case Rep. 2016;5(2):179–183.
   PubMedGoogle Scholar
• Gerischer LM, Siebert E, Janke O, et al. Favorable outcome of interferon-beta associated thrombotic microangiopathy following treatment with corticosteroids, plasma exchange and rituximab: a case report. Mult Scler Relat Disord. 2016;10:63–65.
   PubMed Web of Science ®Google Scholar
• Ben-Amor AF, Trochanov A, Fischer TZ. Cumulative review of thrombotic microangiopathy, thrombotic thrombocytopenic purpura, and hemolytic uremic syndrome reports with subcutaneous interferon β-1a. Adv Ther. 2015;32(5):445–454.
   PubMed Web of Science ®Google Scholar
• Arrambide G. Thrombotic thrombocytopenic purpura-haemolytic uremic syndrome in relapsing-remitting multiple sclerosis patients on high-dose interferon beta. Mult Scler. 2014;20(13):1788–1789.
   PubMed Web of Science ®Google Scholar
• Simbrich A, Thibaut J, Khil L, et al. Drug-use patterns and severe adverse events with disease-modifying drugs in patients with multiple sclerosis: a cohort study based on german claims data. Neuropsychiatr Dis Treat. 2019;15:1439–1457.
   PubMed Web of Science ®Google Scholar
• Dhib-Jalbut S, Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology. 2010;74 Suppl 1:S17–S24.
   PubMedGoogle Scholar
• Watts RA. Musculoskeletal and systemic reactions to biological therapeutic agents. Curr Opin Rheumatol. 2000;12(1):49–52.
   PubMed Web of Science ®Google Scholar
• Fu Y, Zhang N, Ren L, et al. Impact of an immune modulator fingolimod on acute ischemic stroke. Proc Natl Acad Sci U S A. 2014;111(51):18315–18320.
   PubMed Web of Science ®Google Scholar
• Kraft P, Göb E, Schuhmann MK, et al. FTY720 ameliorates acute ischemic stroke in mice by reducing thrombo-inflammation but not by direct neuroprotection. Stroke. 2013;44(11):3202–3210.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Fu Y, Tian D, et al. Combination of the immune modulator fingolimod with alteplase in acute ischemic stroke: a pilot trial. Circulation. 2015;132(12):1104–1112.
   PubMed Web of Science ®Google Scholar
• Li YJ, Chang GQ, Liu Y, et al. Fingolimod alters inflammatory mediators and vascular permeability in intracerebral hemorrhage. Neurosci Bull. 2015;31(6):755–762.
   PubMed Web of Science ®Google Scholar
• Fu Y, Hao J, Zhang N, et al. Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study. JAMA Neurol. 2014;71(9):1092–1101.
   PubMed Web of Science ®Google Scholar
• Wang Z, Kawabori M, Houkin K. FTY720 (fingolimod) ameliorates brain injury through multiple mechanisms and is a strong candidate for stroke treatment. Curr Med Chem. 2020;27(18):2979–2993.
   PubMed Web of Science ®Google Scholar
• Cipriani R, Chara JC, Rodríguez-Antigüedad A, et al. FTY720 attenuates excitotoxicity and neuroinflammation. J Neuroinflammation. 2015;12:86.
   PubMed Web of Science ®Google Scholar
• Ayzenberg I, Hoepner R, Kleiter I. Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations. Ther Clin Risk Manag. 2016;12:261–272.
   PubMed Web of Science ®Google Scholar
• Belliston S, Sundararajan J, Hammond N, et al. Reversible cerebral vasoconstriction syndrome in association with fingolimod use. Int J Neurosci. 2017;127(9):831–834.
   PubMed Web of Science ®Google Scholar
• Moccia M, Albero R, Lanzillo R, et al. Cardiovascular profile improvement during natalizumab treatment. Metab Brain Dis. 2018;33(3):981–986.
   PubMed Web of Science ®Google Scholar
• Elkins J, Veltkamp R, Montaner J, et al. Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurol. 2017;16(3):217–226.
   PubMed Web of Science ®Google Scholar
• O’Connor P, Goodman A, Kappos L, et al. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS study. Neurology. 2014;83(1):78–86.
   PubMed Web of Science ®Google Scholar
• Butzkueven H, Kappos L, Pellegrini F, on behalf of the TYSABRI Observational Program (TOP) Investigators, et al. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psych. 2014;85(11):1190–1197.
   PubMed Web of Science ®Google Scholar
• van Pesch V, Sindic CJ, Fernández O. Effectiveness and safety of natalizumab in real-world clinical practice: Review of observational studies. Clin Neurol Neurosurg. 2016;149:55–63.
   PubMed Web of Science ®Google Scholar
• Gandhi S, Jakimovski D, Ahmed R, et al. Use of natalizumab in multiple sclerosis: current perspectives. Expert Opin Biol Ther. 2016;16(9):1151–1162.
   PubMed Web of Science ®Google Scholar
• Dahlhaus S, Hoepner R, Chan A, et al. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry. 2013;84(10):1068–1074.
   PubMed Web of Science ®Google Scholar
• Tan IL, McArthur JC, Clifford DB, et al. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology. 2011;77(11):1061–1067.
   PubMed Web of Science ®Google Scholar
• Hamidi V, Couto E, Ringerike T, et al. A multiple treatment comparison of eleven Disease-Modifying drugs used for multiple sclerosis. J Clin Med Res. 2018;10(2):88–105.
   PubMedGoogle Scholar
• Pöllmann W, Feneberg W. Current management of pain associated with multiple sclerosis. CNS Drugs. 2008;22(4):291–324.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Christiansen CF, Horváth-Puhó E, et al. Non-steroidal anti-inflammatory drug use and risk of venous thromboembolism. J Thromb Haemost. 2011;9(7):1326–1333.
   PubMed Web of Science ®Google Scholar
• van Zaane B, Nur E, Squizzato A, et al. Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors. J Thromb Haemost. 2010;8(11):2483–2493.
   PubMed Web of Science ®Google Scholar
• Albucher JF, Vuillemin-Azaïs C, Manelfe C, et al. Cerebral thrombophlebitis in three patients with probable multiple sclerosis. Role of lumbar puncture or intravenous corticosteroid treatment. Cerebrovasc Dis. 1999;9(5):298–303.
   PubMed Web of Science ®Google Scholar
• Städler C, Vuadens P, Dewarrat A, et al. Cerebral venous thrombosis after lumbar puncture and intravenous steroids in two patients with multiple sclerosis. ]Rev Neurol (Paris). 2000;156(2):155–159. [
   PubMed Web of Science ®Google Scholar
• Malanga GA, Gangemi E. Intracranial venous thrombosis in a patient with multiple sclerosis. A case report and review of contraceptive alternatives in patients with disabilities. Am J Phys Med Rehabil. 1994;73(4):283–285.
   PubMed Web of Science ®Google Scholar
• Presicci A, Garofoli V, Simone M, et al. Cerebral venous thrombosis after lumbar puncture and intravenous high dose corticosteroids: a case report of a childhood multiple sclerosis. Brain Dev. 2013;35(6):602–605.
   PubMed Web of Science ®Google Scholar
• Al-Hashel JY, Ahmed SF, Alexnader KJ, et al. Cerebral venous thrombosis in a patient with clinically isolated spinal cord syndrome. Case Rep Neurol Med. 2013;2013:364869.
   PubMedGoogle Scholar
• Vandenberghe N, Debouverie M, Anxionnat R, et al. Cerebral venous thrombosis in four patients with multiple sclerosis. Eur J Neurol. 2003;10(1):63–66.
   PubMed Web of Science ®Google Scholar
• Maurelli M, Bergamaschi R, Candeloro E, et al. Cerebral venous thrombosis and demyelinating diseases: report of a case in a clinically isolated syndrome suggestive of multiple sclerosis onset and review of the literature. Mult Scler. 2005;11(2):242–244.
   PubMed Web of Science ®Google Scholar
• Hellwig K, Chen LH, Stancyzk FZ, et al. Oral contraceptives and multiple sclerosis/clinically isolated syndrome susceptibility. PLoS ONE. 2016;11(3):e0149094.
   PubMed Web of Science ®Google Scholar
• Avasarala J, Parti N. Can aspirin minimize stroke risk and new lesion formation in multiple sclerosis? Front Neurol. 2018;9:613.
   PubMed Web of Science ®Google Scholar
• Tsau S, Emerson MR, Lynch SG, et al. Aspirin and multiple sclerosis. BMC Med. 2015;13(1):153.
   PubMedGoogle Scholar
• Arachchillage D, Laffan M. What is the appropriate anticoagulation strategy for thrombotic antiphospholipid syndrome? Br J Haematol. 2020;189(2):216–227.
   PubMed Web of Science ®Google Scholar
• Erkan D, Harrison MJ, Levy R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007;56(7):2382–2391.
   PubMedGoogle Scholar
• Kraus J, Oschmann P. The impact of interferon-beta treatment on the blood-brain barrier. Drug Discov Today. 2006;11(15-16):755–762.
   PubMed Web of Science ®Google Scholar
• Wanve M, Kaur H, Sarmah D, et al. Therapeutic spectrum of interferon-β in ischemic stroke. J Neurosci Res. 2019;97(2):116–127.
   PubMed Web of Science ®Google Scholar
• Kunze R, Urrutia A, Hoffmann A, et al. Dimethyl fumarate attenuates cerebral edema formation by protecting the blood-brain barrier integrity. Exp Neurol. 2015;266:99–111.
   PubMed Web of Science ®Google Scholar
• Nishihara H, Shimizu F, Sano Y, et al. Fingolimod prevents blood-brain barrier disruption induced by the sera from patients with multiple sclerosis. PLoS One. 2015;10(3):e0121488.
   PubMed Web of Science ®Google Scholar
• Nishihara H, Maeda T, Sano Y, et al. Fingolimod promotes blood-nerve barrier properties in vitro. Brain Behav. 2018;8(4):e00924.
   PubMed Web of Science ®Google Scholar
• Lühder F, Kebir H, Odoardi F, et al. Laquinimod enhances Central nervous system barrier functions. Neurobiol Dis. 2017;102:60–69.
   PubMed Web of Science ®Google Scholar
• Elkind MSV, Veltkamp R, Montaner J, et al. Natalizumab in acute ischemic stroke (ACTION II): A randomized, placebo-controlled trial). Neurology. 2020;95(8):e1091–e1104.
   PubMed Web of Science ®Google Scholar
• Aloizou AM, Siokas V, Pateraki G, et al. Thinking outside the ischemia box: Advancements in the use of multiple sclerosis drugs in ischemic stroke. J Clin Med. 2021;10(4):630.
   Web of Science ®Google Scholar
• Ifergan I, Wosik K, Cayrol R, et al. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann Neurol. 2006;60(1):45–55.
   PubMed Web of Science ®Google Scholar
• Pihl-Jensen G, Tsakiri A, Frederiksen JL. Statin treatment in multiple sclerosis: a systematic review and Meta-analysis. CNS Drugs. 2015;29(4):277–291.
   PubMed Web of Science ®Google Scholar
• Ciurleo R, Bramanti P, Marino S. Role of statins in the treatment of multiple sclerosis. Pharmacol Res. 2014;87:133–143.
   PubMed Web of Science ®Google Scholar
• Chataway J, Schuerer N, Alsanousi A, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet. 2014;383(9936):2213–2221.
   PubMed Web of Science ®Google Scholar
• Hoepner R, Bagnoud M, Pistor M, et al. Vitamin D increases glucocorticoid efficacy via inhibition of mTORC1 in experimental models of multiple sclerosis. Acta Neuropathol. 2019;138(3):443–456.
   PubMed Web of Science ®Google Scholar
• Vokó Z, Hollander M, Hofman A, et al. Dietary antioxidants and the risk of ischemic stroke: the Rotterdam Study. Neurology. 2003;61(9):1273–1275.
   PubMed Web of Science ®Google Scholar
• Kocot J, Luchowska-Kocot D, Kiełczykowska M, et al. Does vitamin C influence neurodegenerative diseases and psychiatric disorders? Nutrients. 2017;9(7):659.
   PubMed Web of Science ®Google Scholar
• Ramírez-Salazar SA, Herren C, McCartney J, et al. Dietary insights in neurological diseases. Curr Neurol Neurosci Rep. 2021;21(10):55.
   PubMed Web of Science ®Google Scholar
• Rai SN, Singh P, Steinbusch HWM, et al. The role of vitamins in neurodegenerative disease: an update. Biomedicines. 2021;9(10):1284.
   PubMed Web of Science ®Google Scholar
• Evans E, Piccio L, Cross AH. Use of vitamins and dietary supplements by patients with multiple sclerosis: a review. JAMA Neurol. 2018;75(8):1013–1021.
   PubMed Web of Science ®Google Scholar
• Perry VH. Contribution of systemic inflammation to chronic neurodegeneration. Acta Neuropathol. 2010;120(3):277–286.
   PubMed Web of Science ®Google Scholar
• Fisher K, Cuascut F, Rivera V, et al. Current advances in pediatric onset multiple sclerosis. Biomedicines. 2020;8(4):71.
   PubMed Web of Science ®Google Scholar
• Poellmann W, Starck M, Kuempfel T, et al. Changing course of multiple sclerosis (MS) after stroke: Excessive disease activity in a MS patient after cerebral infarction (P1.122). Neurology. 2015;84(14 Suppl.):P1.122.
   Google Scholar